ArvinIG

Hi @koppis2, The best contact for your query is : newaccounts.uk@ig.com. The account opening team will be able to give you an update on your application. All the best - Arvin

Hi @Taiki, Thank you for your message. Your request was submitted to the dealing desk to be reviewed. All the best - Arvin

Hi @Taiki, Thank you for your message. Your request was submitted to the dealing desk to be reviewed. All the best - Arvin

SENTIMENT SENTIMENT INDICATORS: USING IG CLIENT SENTIMENT The IG Client Sentiment (IGCS) is unique, proprietary and potentially helpful to traders. The article will outline the following illustrative points: What is IG Client Sentiment (IGCS)? Sentiment Indicators IGCS as a Leading Indicator IGCS as a Technical Indicator: Summary WHAT IS IG CLIENT SENTIMENT (IGCS)? IG Client Sentiment (IGCS) is a tool that traders can use in conjunction with a broader technical and/or fundamental strategy. IGCS incorporates retail trader positioning (long and short) to formulate a sentiment bias. This is represented in percentage form (see image below) which aids traders in identifying market imbalances which could lead to possible opportunities. IGCS on EUR/USD: SENTIMENT INDICATORS Sentiment indicators are few and far between. The two most well-known are open interest in options, which largely applies to stocks, and the Commitment of Traders Report (CoT). What sets IGCS apart is the large sample size of retail traders which deliver more usable data in terms of indicator readings, multiple market data sets (FX, equities commodities) and timely updates for these markets which are refreshed several times daily. IGCS AS A LEADING INDICATOR The use of IGCS as a technical indicator can allow traders to confirm or refute signals produced by their wider trading strategy. Both fundamental and other technical techniques are used to gauge trends, ranges, potential reversals etc. so incorporating IGCS provides another layer of data to help verify a hypothesis. IGCS can be considered as a leading indicator as it uses past and current data to project possible future price movements however, as IGCS (retail) covers only one component of the market equation, traders should not rely solely on the IGCS tool for trading decisions. Simply put, retail traders contribute only a certain percentage of market input so naturally other factors will have influence on the respective market. For example, the EUR/USD chart below shows the projectible nature that can occur with IGCS. The highlighted are on the chart exhibits an increase in net short positions from retail traders which coincided with a rise in price action (EUR appreciation) on the price chart itself. IGCS EUR/USD: IGCS AS A TECHNICAL INDICATOR: SUMMARY We have shown how sentiment/IGCS can be a unique, proprietary and potentially helpful addition to a trader’s approach. In subsequent IGCS articles in this market sentiment sub-module, we will go through the implementation and flexibility of this tool in varying trading circumstances. Looking to trade in a simulated environment to better learn strategies, tactics and approach? Click here to request a free demo with IG group. DailyFX provides forex news and technical analysis on the trends that influence the global currency markets. DISCLOSURES Warren Venketas , Analyst , DailyFX 29 December 2021

Canada is grappling with a housing market crisis that has seen the median family home soar 20% in a year to C$720,850. As inflation surges, will the Bank of Canada raise interest rates in 2022? Source: Bloomberg Forex Inflation Canada Bank Price Monetary policy USD/CAD is one of the most popular currency pairs on IG. And currently, 56% of clients are long on the market, signalling investor uncertainty as the markets price in the chances that the US Federal Reserve could raise rates before the Bank of Canada. But as its housing market rises out of control, Canada’s central bank is coming under intense pressure to tighten monetary policy. USD/CAD: Inflation and interest rates According to this month’s renewal of Canada’s Monetary Policy Framework, ‘the primary objective of monetary policy is to maintain low, stable inflation over time.’ And in common with every central bank across the western world, the Bank of Canada has struggled with this mandate in 2021. Canada’s CPI inflation rate is at a multi-decade high of 4.7%. This may be lower than the US’s 6.8%, the UK’s 5.1%, and the EU’s 4.9%. However, Canada’s central bank is tasked with preserving the inflation rate at between 1% and 3%— and inflation is expected to continue rising until mid-2022. But at its December interest rate meeting, the bank decided to hold the base rate at 0.25%, citing how the Omicron variant has ‘injected renewed uncertainty,’ and that ‘accommodative financial conditions are still supporting economic activity.’ Much like the Federal Reserve, it has also dropped the word ‘transitory’ to describe the current inflationary spiral. Justifying its decision, the bank said that ‘Canada’s economy grew by about 5.5% in the third quarter…GDP is about 1.5% below its level in the last quarter of 2019 before the pandemic began.’ Meanwhile, Statistics Canada’s November Labour Force Survey found that ‘the unemployment rate fell to 6.0%, within 0.3 percentage points of what it was in February 2020.’ And the country had 912,600 job vacancies, a record high. The bank summarised that it remains ‘committed to holding the policy interest rate at the effective lower bound until economic slack is absorbed so that the 2% inflation target is sustainably achieved…sometime in the middle quarters of 2022.’ However, maintaining this ultra-loose monetary policy will come at a cost. Source: Bloomberg USD/CAD: red-hot housing market Across the western nations, rapidly rising housing costs is fast becoming a crisis. Wage increases are being eclipsed by house price rises— and arguably, the Great White North has been one of hardest hit. The Canadian Real Estate Association estimates that the national average home price rose 19.6% over the past year to C$720,850 in November 2021. And according to Royal LePage CEO Phil Soper, prices will rise a further 10.5% in 2022, due to ‘to a level of demand that will continue to outpace inventory, keeping prices rising on a steep upward trajectory.’ With average prices in Toronto and Vancouver already surpassing the C$1 million mark, Soper believes the increases will continue as buyers take ‘advantage of increased savings and record-low interest rates.’ Prices will also be supported by high immigration and the continued transition to remote working. After failing to win a majority in September’s snap election, Prime Minister Justin Trudeau has instructed Housing Minister Ahmed Hussen to discourage property investment by reviewing the rules around deposits as well as housing policies to curb ‘excessive profits.’ Hussen plans to ‘reduce speculative demand in the market and help cool these astronomical increases in prices.’ He has already imposed a 1% tax on foreign-owned vacant homes and intends to ban the controversial practice of blind bidding. He is also proposing C$4 billion for affordable housing but has come up against ‘NIMBYism’ and ‘unreasonable opposition to affordable housing in neighbourhoods.’ New Zealand implemented similar laws to stop property speculation back in March. However, average prices still rose 31% over the year to July to a record NZ$937,000. Its Reserve Bank has finally increased its base rate to 0.75% and plans for further rises in the new year. But Conference Board of Canada economist Sasan Fouladirad believes that Canada will not raise rates before the US, as ‘Canadian household debt is on average much higher than the US…we expect the Bank to wait until June next year.’ However, as housing inflation continues to skyrocket, the argument for raising rates continues to grow stronger. Trade 100+ FX pairs with the UK’s No. 1 retail forex provider.* Enjoy fast execution, low spreads – plus we’ll never fill your order at a worse price. Learn more about our forex trading platform or create an account to start trading today. Charles Archer | Financial Writer, London 29 December 2021

Hi @Levo, Could you please confirm that your Face ID is activated on your phone settings ? On the IG app if you select Account at the bottom right then Settings, then scroll down to Account settings you should be able to see the Touch ID and Face ID options to toggle on. Feel free to reach out to helpdesk.uk@ig.com with a screenshot for further assistance. I hope that it helps. All the best - Arvin

Please see the expected dividend adjustment figures for a number of our major indices for the week commencing 27th December 2021. These are projected dividends and likely to change. IG cannot be held responsible for any changes made. Dividends highlighted in red include a special dividend, therefore some or all of the amount will not be adjusted. Amount in brackets is the expected adjustment after special dividends excluded (where shown on major indices). Dividend adjustments due to be posted on a bank holiday will usually be posted on the previous working day. If you have any queries or questions on this please let us know in the comments section below. For further information regarding dividend adjustments, and how they affect your positions, please take a look at the video. NB: All dividend adjustments are forecasts and therefore speculative. A dividend adjustment is a cash neutral adjustment on your account. Special Dividends: Index Bloomberg Code Effective Date Summary Dividend Amount RTY TRTX 28/12/2021 Special Div 0.07 RTY FSP 30/12/2021 Special Div 0.32 RTY ACRE 30/12/2021 Special Div 0.33 RTY HIFS 31/12/2021 Special Div 0.75 How do dividend adjustments work? This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

The Nvidia share price has risen 6,580% since mid-2015, as global demand for microchips surges, and it continues its attempts to takeover UK rival Arm. Could it soar into 2022 and beyond? Source: Bloomberg Shares Nvidia Integrated circuit Price Competition and Markets Authority SoftBank Group The Nvidia (NASDAQ: NVDA) share price is a US stock success story. In mid-2015, the microchip specialist was a penny stock by US standards, trading for under $5 a share. On 29 November 2021, it had made a modest gain of 6,580%, reaching a record $334. By comparison, the NASDAQ Composite Index rose roughly 200% over the same timescale. Nvidia’s core product, semiconductors (or microchips) are often likened to the ‘brain cells’ of a computer, as the nucleus is to a biological cell. And record demand for the technology is set to continue. However, Nvidia was trading for only $116 as recently as March. And in the past three weeks, it’s fallen 12% to $294, as its proposed multi-billion-dollar takeover plan for UK rival Arm comes under fire. Nvidia share price: just out of Arm’s reach Nvidia first expressed an interest in taking over its privately held rival in September 2020. The move was met with immediate national security and anti-trust opposition. Arm’s cutting-edge energy-efficient chip architectures are used in 95% of smartphones worldwide. Moreover, the company is widely viewed as a showpiece for the UK technology sector. And since Nvidia’s first proposal, Arm has nearly doubled in value from $40 billion to $75 billion in a little over a year. After finding ‘significant competition concerns’ during its initial investigations, the UK’s Competition and Markets Authority (CMA) has begun a full ‘phase 2’ probe into the proposed merger. And the European Commission (EC) has also launched its own investigation, with EC Executive Vice President Margrethe Vestager commenting that ‘the acquisition of Arm by Nvidia could lead to restricted or degraded access to Arm’s IP, with distortive effects in many markets.’ But it’s the US Federal Trade Commission (FTC) that has truly sent both companies back to the drawing board. Bureau of Competition Director Holly Vedova said she wanted to stop the ‘largest semiconductor chip merger in history to prevent a chip conglomerate from stifling the innovation pipeline for next-generation technologies.' Calling Arm the ‘Switzerland’ of chipmakers, the FTC is suing Nvidia as it believes the deal would ‘allow the combined firm to unfairly undermine Nvidia’s rivals.’ With all three regulators against the takeover in its current form, it’s hard to see how it could continue. But there were no issues when Arm was bought by Japanese giant SoftBank for $32 billion in 2016. And if SoftBank CEO Masayoshi Son is right in believing that the deal will eventually go through, the Nvidia share price could skyrocket. Source: Bloomberg Money, money, money In Q3 results last month, Nvidia reported record revenue of $7.1 billion, up 50% compared to the same quarter last year, and 9% quarter-over-quarter. This allowed the company to pay out quarterly dividends of over $100 million. This performance was largely driven by its best-ever gaming and data centre results. CEO Jensen Huang said that ‘demand for Nvidia AI is surging, driven by hyper-scale and cloud scale-out, and broadening adoption by more than 25,000 companies. NVIDIA RTX has reinvented computer graphics.’ Further ‘Omniverse was a major theme…(which) brings together NVIDIA’s expertise in AI, simulation, graphics and computing infrastructure. This is the tip of the iceberg of what’s to come.’ But Nvidia will face stiff competition from competitors Intel and AMD. The shortage of microchips means that the demand for skilled workers is higher than ever — and in good news for employees, this means pay rises. Intel is spending $2.4 billion next year on staff salaries, comprised of $1 billion in cash and a further $1.4 billion in shares, to help ‘win the fierce battle for talent in today’s competitive market.’ Its 110,000-strong workforce will receive an average raise of $21,000 per year, and Nvidia will likely be forced to compete financially for workers. But as the microchip shortage continues, Huang told investors that Nvidia had ‘secured guaranteed supply, very large amounts of it, quite a spectacular amount of it from the world's leading foundry.’ Perhaps that’s why UBS analyst Timothy Arcuri made Nvidia one of his ‘top picks’ for 2022. While the Arm takeover may be on hold for now, the Nvidia share price could continue its bull run into 2022. Go short and long with spread bets, CFDs and share dealing on 16,000+ shares with the UK’s No.1 platform.* Learn more about trading shares with us, or open an account to get started today. * Best trading platform as awarded at the ADVFN International Financial Awards 2021 Charles Archer | Financial Writer, London 24 December 2021

Hi @Edgar_707, All our demo accounts are using leverage, there are no option to activate or deactivate leverage on the demo accounts. All the best - Arvin

Hi @nickpr, You can use the below thread to submit a stock request. Could you please clarify if you want this stock to be added on share dealing or leverage account? On leverage account the market cap would to low to be added. Thank you - Arvin

Hi @Edgar_707, All Demo accounts are using leverage. The leverage is automatically applied on the the dealing ticket. You can find the margin requirements on the info tab of the dealing ticket : The margin will display on the ticket: All our demo accounts are using leverage, there is no toggle on button. I hope that it helps. All the best - Arvin

Illustration taken December 11, 2021. REUTERS/Dado Ruvic COPENHAGEN, Dec 22 (Reuters) - Getting a third dose of either Pfizer-BioNTech's (PFE.N) or Moderna's (MRNA.O) COVID-19 vaccine offers a "significant increase" in protection against the Omicron variant in elderly people, according to a Danish study published on Wednesday. The study, which is not yet peer-reviewed, investigated the effectiveness of COVID-19 vaccines that use so-called mRNA technology against the Delta variant and the new, more infectious Omicron variant. "Our study contributes to emerging evidence that BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) primary vaccine protection against Omicron decreases quickly over time, with booster vaccination offering a significant increase in protection," the authors wrote in the study. The study was conducted by researchers at Denmark's top infectious disease authority, Statens Serum Institut (SSI). It analysed data from three million Danes gathered between Nov. 20 and Dec. 12. Among those who recently had their second vaccine dose, effectiveness against Omicron was measured at 55.2% for Pfizer-BioNTech and 36.7% for Moderna, compared to unvaccinated people. But that protection quickly waned over the course of five months, the researchers said. "We see that the protection is lower and decreases faster against Omicron than against the Delta variant after a primary vaccination course," study author Palle Valentiner-Branth said. However, a third dose of Pfizer-BioNTech's vaccine restored protection to 54.6% in people aged 60 or more who had been inoculated 14 to 44 days earlier, compared to those with only two doses. The study confirms the findings of a recent British study, which also showed a rapid decline in protection against Omicron over time and an increase following a booster with Pfizer-BioNTech's vaccine. "In light of the exponential rise in Omicron cases, these findings highlight the need for massive rollout of vaccinations and booster vaccinations," the researchers said.

Hi @Trader1112, The market cap to add stock on leverage accounts is $1bn USD, if it is close to that amount the dealing might consider adding it. All the best - Arvin

The Pfizer share price has more than doubled since its March 2020 low of $29. At $59 today, will continued investment and a resurgent Omicron-fuelled pandemic see it explode further into the new year? Source: Bloomberg Shares Pfizer Vaccine COVID-19 pandemic Medication Pfizer–BioNTech COVID-19 vaccine The Pfizer (NYSE: PFE) share price has been one of the best-performing stocks of 2021. Like the rest of the NYSE, it fell sharply at the beginning of the covid-19 pandemic, from $38 on 17 January, to $27 by 20 March 2020. Since then, it’s been fairly volatile, peaking at $41 on 11 December 2020, and again to $49 on 20 August 2021, while also dipping to as low as $33 in-between. However, since 15 October, it’s risen consistently to a high of $59 today, as demand for its patented Comirnaty coronavirus vaccine continues to remain strong. And cheerleaders for the pharmaceutical company believe it could go further. Pfizer share price: 2021 acquisitions The key problem for long-term Pfizer investors is that its meteoric share price rise is due almost exclusively to the success of its trailblazing coronavirus vaccine, developed in partnership with BioNTech. But through a combination of vaccination and natural herd immunity, coronavirus will eventually no longer be treated as a worldwide medical emergency. Knowing this, Pfizer is using its newfound wealth to acquire strategically important companies to prepare for the inevitable. In April, it bought Amplyx Pharmaceuticals, which develops treatments for immuno-compromised individuals. Currently in phase 2 clinical trials, its cutting-edge anti-fungal drug, Fosmanogepix, could be the first to be approved by the US Food and Drug Administration (FDA) in almost two decades. And in August, Pfizer bought out Trillium Therapeutics for $2.26 billion. The company is developing treatments that boosts the immune system’s ability to identify and destroy cancer cells. Then last week, Pfizer announced plans to spend $6.7 billion acquiring stomach and intestinal disease research firm Arena Pharmaceuticals. And it’s offering $100 per share, a 100% premium on the company’s prior closing price. Arena’s flagship drug Etrasimod could be the key to treating inflammatory bowel disease, a condition that affects 10-15% of the global population. It’s also developing Olorinad, which it hopes will soon be approved to treat pain associated with gastrointestinal disorders. Mike Gladstone, Global President of Inflammation & Immunology commented that together the two companies could develop ‘therapies for patients with debilitating immuno-inflammatory diseases with a need for more effective treatment options.’ The success of any of these new treatments could see Pfizer’s share price soar. Source: Bloomberg Pandemic profits According to Q3 results, Pfizer generated $24.1 billion in revenue, representing 130% operational growth. However, 60% of this revenue, or $14.6 billion, came from sales of its coronavirus vaccine Comirnaty. And full-year vaccine revenue is anticipated to be $36 billion, as a result of 2.3 billion doses. Excluding vaccine sales, revenue only grew 7% to $11.1 billion. With such a high proportion of revenue coming from a non-renewable resource, Chief Financial Officer Frank D’Amelio believes that it is essential for Pfizer ‘through partnerships and bolt-on acquisitions to gain access to cutting-edge platforms, science and technologies that could potentially bolster our growth in the latter half of this decade.’ Mizuho analyst Vamil Divan believes the company is ‘reasonably valued,’ but that ‘questions still remain on the longevity of the revenue streams, as well as how well Pfizer will be able to leverage that success into the rest of their business.’ But demand for Pfizer’s vaccine remains strong for now. In response to the Omicron variant, the European Commission is purchasing an additional 200 million Comirnaty vaccines in 2022, bringing the total ordered up to 650 million. Meanwhile, the UK has ordered 2.75 million courses of its oral coronavirus antiviral pill, Paxlovid, through 2022. In clinical trials, the drug was shown to be capable of preventing 90% of hospitalisations and death in high-risk patients. The US government has also ordered 10 million courses of the pill, with approval expected from the FDA imminently. CEO and Chairman Albert Bourla believes it will be ‘a critical tool to help quell the pandemic,’ while Eric Topol, director of the Scripps Research Translational Institute thinks ‘if we had an unlimited supply of these pills, it could have an extraordinary impact on preventing illness.’ The Pfizer share price could rise even further in 2022. SVB Leerink analyst Geoffrey Porges believes that its revenue could soar to $101.3 billion in 2022, as countries desperate to avoid further lockdowns continue to mass-order the company’s wares. But when the pandemic eventually runs out of steam, Pfizer will be left depending on a fair return on its various corporate investments. It’s probably fair to expect further volatility as it implements its long-term plan. Go short and long with spread bets, CFDs and share dealing on 16,000+ shares with the UK’s No.1 platform.* Learn more about trading shares with us, or open an account to get started today. * Best trading platform as awarded at the ADVFN International Financial Awards 2021 Charles Archer | Financial Writer, London 23 December 2021

The Rentokil share price soared to a record 636p in November. While overpaying for rival Terminix has seen it fall to 570p for now, this proposed new entity will be the largest pest control company in the world. Source: Bloomberg Indices Shares Rentokil Initial Terminix Pest control Price The Rentokil (LON: RTO) share price has been volatile over the past few days. This isn’t normal for a FTSE 100 stock, much less one that specialises in the essential, but prosaic world of pest control. The company has been enjoying a stellar run over the past two years. In line with the rest of the FTSE 100, it fell 29% from 508p on 21 February 2020 to 362p on 27 March 2020. While the rest of the index has yet to completely recover from the mini-crash, Rentokil’s share price soared to a record high of 636p by 12 November 2021, as pandemic-driven demand for its hygiene services rocketed. The stock then dropped slightly, to 624p by the morning of 14 December. Then Rentokil announced a takeover deal with competitor Terminix. While the initial reaction saw its share price rise, by the end of the next trading day, it had fallen 16% to 522p. However, it was the top FTSE 100 riser yesterday, recovering to 570p. But it’s clear some investors were not happy with the detail of the proposed merger. Rentokil share price: Terminix takeover Rentokil has agreed to buy Terminix for $6.7 billion. And encouragingly, this is no hostile takeover, as both boards have approved the deal. 643 million new Rentokil shares will be created and handed over to Terminix shareholders, along with $1.3 billion in hard cash. The scale of the deal spooked some investors — as it values Terminix shares at $55 apiece, a 47% premium over Terminix’s closing price on 13 December, and a 32.5% premium over its previous 90-day volume-weighted average. Moreover, Terminix shareholders will own 26% of the merged company. But if the deal gains regulatory and shareholder approval, it will allow Rentokil to massively expand its business in the key North America region, which represents 51% of the global pest control market. Furthermore, the new company will be the largest pest control services company in the world, with 56,000 employees and a five million-strong customer base. In its regulatory filing, Rentokil said that North America has a ‘fragmented market comprising over 20,000 pest control companies.’ There is a significant opportunity for the new entity to use its ‘complementary and synergistic combination’ to grow market share in the lucrative $11 billion region. And in October’s Q3 results, Rentokil said that ‘our pest control business in North America continued to demonstrate very strong momentum, growing revenues by 24.6%’ despite ‘some (pandemic-caused) labour shortages.’ Source: Bloomberg The future of pest control? Rentokil Chairman Richard Solomons and Terminix CEO Andy Ransom will retain their roles in the combined group. Solomons commented that it ‘will have a highly talented and experienced management team able to more effectively create value and enhance long-term growth.’ And Ransom argues that the deal ‘will create the global leader in commercial, residential and termite pest control.’ He further believes that they are ‘two highly complementary businesses,’ and that ‘this is a win-win-win for colleagues, customers and shareholders.’ According to both companies, the global pest control market has an estimated 2020 worth of around $22 billion and is ‘estimated to grow at between 4.5% and 5%+ over the medium term.’ Analysts at Peel Hunt hailed the deal as a ‘transformational acquisition.’ Meanwhile, the Omicron variant of coronavirus is starting to chill the spines of leaders worldwide. In the US, White House Chief Medical Adviser Anthony Fauci believes that ‘it is quite likely that we are going to see in some sections of the country a significant stress on the hospital system.’ And in a press conference yesterday, PM Boris Johnson told the public that ‘we are looking at all kinds of things to keep Omicron under control, and we will rule nothing out.’ With travel and social restrictions being reimposed across Europe, Rentokil’s services will remain in strong demand. In Q3, ongoing revenue, excluding disinfection services, grew by 14.5% to £750.2 million. And the companies expect to generate at least $150 million in cost savings within three years of merger completion. And while the Rentokil share price has dipped slightly, it’s up 158% over the past five years. And a year from now, it plans to be the global market leader. Of course, the best laid plans of mice and men often go awry… Go short and long with spread bets, CFDs and share dealing on 16,000+ shares with the UK’s No.1 platform.* Learn more about trading shares with us, or open an account to get started today. * Best trading platform as awarded at the ADVFN International Financial Awards 2021 Charles Archer | Financial Writer, London 21 December 2021

Hi @amrutbairy, We already raised that feedback to the relevant department. There is no ETA at this point in time. Please keep in mind that depositing via card is immediate. The longest time frame is for withdrawals 1-3 business days. Thank you - Arvin

Hi @amrutbairy, Unfortunately, We do not offer such deposit method. You can use Cards, Bank transfer and Paypal. All the best - Arvin

Hi @Midge25, That would be a query for the Corporate Action team. Have you received an email from in regards to your Bacanora position? If so please reply to that email with your question. Alternatively reach out to helpdesk.uk@ig.com or use our live chat feature on the IG website. All the best - Arvin

Hi @Trader1112, The market cap is too low on ALLR to be added. The stock was added on share dealing platform. All the best - Arvin

Hi @GorillaForSale, ISA rules state that you can only pay into a single stocks and shares ISA each tax year. You are free to open an additional ISA with a different provider each new tax year, but can only pay money into one. With IG, you can invest in a single stocks and shares ISA via two separate account types: share dealing and/or an IG Smart Portfolio. This means that if it suits your investment strategy to do so, you can open an IG Smart Portfolio and share dealing account in the same tax year and split your annual ISA allowance between them. I hope that it helps. All the best - Arvin

NASDAQ 100, ASX 200, NIKKEI 225, BUILD BACK BETTER, OMICRON – ASIA PACIFIC INDICES BRIEFING Nasdaq 100, S&P 500, Dow Jones sink to start off the new week US fiscal stimulus disappointment and Omicron woes were eyed ASX 200 and Nikkei 225 resilient despite Wall Street turbulence MONDAY’S WALL STREET TRADING SESSION RECAP Market sentiment deteriorated to start off the new week, with the Nasdaq 100, S&P 500 and Dow Jones sinking 1.06%, 1.14% and 1.23% respectively on Monday. The VIX index, also known as the market’s preferred ‘fear gauge’, closed at its highest in almost 2 weeks. Financials (-1.9%), materials (-1.8%) and industrials (-1.7%) were the worst-performing sectors within the S&P 500. A combination of US fiscal stimulus disappointment and Omicron Covid-19 variant woes likely played a key role in markets. Over the weekend, US Senator Joe Manchin dashed hopes of getting President Joe Biden’s US$ 2 trillion ‘Build back Better’ economic bill passed. By not supporting the bill, it will almost be impossible for Democrats to pass the legislation without any Republican backing in the 50-50 Senate. Meanwhile, threats of Covid-related restrictions in Europe also likely dented risk appetite. The United Kingdom is debating whether or not to impose fresh restrictions as the Netherlands locked down until the middle of January. Germany imposed a quarantine on travelers from the UK, and the Bundesbank warned that the nation’s economy may shrink this quarter. NASDAQ 100 TECHNICAL ANALYSIS Despite recent weakness in Nasdaq 100 futures, prices were unable to take out the key 15503 – 15580 support zone on the 4-hour chart below. Still, the index has confirmed a breakout under the 200-period SMA. A bearish crossover between that and the 50 line offers a downward technical bias. Clearing the support zone exposes the late October low at 15273. Otherwise, a push higher has the 50-period line in focus. NASDAQ 100 4-HOUR CHART Chart Created in TradingView TUESDAY’S ASIA PACIFIC TRADING SESSION Following the disappointing session on Wall Street, Asia-Pacific markets could be at risk to more of the same on Tuesday. New Zealand announced that it will be delaying reopening its borders due to the Omicron variant. However, S&P 500 futures have been cautiously recovering since the Wall Street close, suggesting that some consolidation could be in store. While the Omicron variant now makes up for about 75% of new Covid cases in the US, a lack of strict lockdowns could keep market sentiment from noticeably deteriorating as deaths remain relatively low. Japan’s Nikkei 225 and Australia’s ASX 200 are up 1.6% and 0.4% in morning trade. ASX 200 TECHNICAL ANALYSIS The ASX 200 remains in a consolidative setting, but a bearish Head and Shoulders chart pattern could be in the process of forming. Prices are also testing the 200-period SMA, which appears to be maintaining the broader upside focus. The index is also being guided lower by a near-term falling trendline from August. Clearing the line exposes the right shoulder around 7480. Immediate support seems to be the 7207 – 7096 zone. ASX 200 – DAILY CHART Chart Created in TradingView Daniel Dubrovsky, Strategist for DailyFX.com 21 December 2021 To contact Daniel, use the comments section below or @ddubrovskyFX on Twitter

Does the Aptamer IPO make it the next Biotech stock to watch? Biotech stock Aptamer is launching its IPO on 22 December, just three months after Oxford Nanopore. Does the York-based start-up's cutting-edge medical technology make it the next stock to watch? Source: Bloomberg Shares Aptamer IPO Biotechnology Vaccine Disease At 8am on Wednesday, Biotech stock Aptamer will launch its Initial Public Offering (IPO) on the FTSE AIM Index. The company is pricing its shares 117p and is raising £10.8 million by selling 9.2 million new shares, giving the company a market cap of £80.7 million. To prevent any post-IPO share price volatility, the management team’s significant shareholdings, including CEO Arron Tolley’s 23% stake, are locked in for a year. Aptamer IPO: breakthrough technology The company is named for aptamers; ‘oligonucleotide molecules, selected from large libraries to bind a specific target.’ In plain English, aptamers are a synthetically produced alternative to antibodies. They can attach to the surface of larger molecules that antibodies cannot bind with due to their larger size. This makes them extremely useful in multiple applications, and especially in medicine. Aptamer treatments are a relatively new technology, with the first being approved by the US Food and Drug Administration as late as 2004. Antibodies, on the other hand, have been helping medics since the smallpox vaccine was developed by Edward Jenner in 1798. The coronavirus vaccines work by training the body’s immune system to develop antibodies to fight the disease. And while traditional antibodies are extremely useful, aptamers have the potential to be the next medical breakthrough. They could even be the key to curing currently untreatable illnesses. In addition, they can also be used for medical diagnosis; the company is working with Cancer Research UK on a leukaemia detection project, and with AstraZeneca on kidney disease. According to Tolley, another significant advantage of aptamers is the ‘speed of discovery. It takes us on average a couple of months to develop aptamers but the very fastest we can do it in is 17 days, when it can take four months and in some cases over a year to develop an antibody.’ Source: Bloomberg Aptamer IPO: the next Biotech stock to watch? Aptamer has developed ‘Optimer binders,’ which it describes as ‘next-generation aptamers.’ Tolley says they are being used by ‘75 per cent of the top 20 global pharmaceutical companies…the well-established global antibody market, is currently worth over $145.7 billion per annum.’ He further commented that ‘we noticed there was a need in the market for molecules that could plug the gap where antibodies failed to be successful.’ The Biotech company’s revenue has risen 62% since 2019 and totalled £1.6 million in the 15 months to 30 June. However, it lost £2.9 million over the same period. But as a growth stock, significant losses incurred from research and development (R&D) come with the territory. Fellow Biotech stock Oxford Nanopore also had its IPO on this year. Initially valued at 425p, its shares have already risen to 672p in just three months, giving the company a £5.5 billion market cap. Like Aptamer, it has also developed a specialised medical technology. The company’s products analyse DNA by moving DNA samples through tiny holes (nanopores) and measuring how they react to electrical currents. With both companies based on or next to university campuses, an investment comparison may be too tempting for investors to ignore. However, it’s easy to remember the success stories. The market graveyard is littered with hundreds of failed Biotech stocks. During the 2000s, the UK was touted as a Biotech market leader — but more than a third collapsed within three years of the 2008 credit crunch. With some analysts expecting another market correction soon, indebted Biotech stocks pursuing ultra-advanced technology could soon once again be in trouble. Of course, every stock market giant started out with an IPO and a dream… How many providers let you trade IPOs before the listing, participate in IPOs and trade IPO stocks right after their full listing?* Only us, the UK’s No.1 trading provider.** Find out more about IPO trading with us or open an account to trade IPOs now. * Based on our IPO offering that includes pre-IPO grey markets, primary market access, and trading and investing on the secondary market. ** Based on revenue excluding FX (published financial statements, June 2020). Charles Archer | Financial Writer, London 21 December 2021

Hi @DarkMatter731, Both were added to share dealing accounts. All the best - Arvin

Hi @tonyramirez, The development team came back to me. They are working on a costs and charges calculator (which will include overnight funding) being added to the deal ticket in the first half of 2022. All the best - Arvin

Hi @twu1234, Could you please send these details to helpdesk.uk@ig.com. It will need to be investigated by the IT team to come back to you with a solution. Thank you - Arvin